טוען...
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
BACKGROUND: Vaccines are urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike protein of SARS-CoV-2. METHODS: This phase 2, rando...
שמור ב:
| הוצא לאור ב: | Vaccine |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Moderna Therapeutics. Published by Elsevier Ltd.
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7871769/ https://ncbi.nlm.nih.gov/pubmed/33707061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2021.02.007 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|